Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Cottu

Showing results (121-130 of 140) with videos related to

Pageof 14
Sort By:
European Journal of Cancer (Oxford, England : 1990)|September 30, 2018
UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancerMario Campone, Magali Lacroix-Triki, Lise Roca, et al.
Ebiomedicine|May 8, 2024
Association between endocrine adjuvant therapy intake timing and disease-free survival in patients with high-risk early breast cancer: results of a sub-study of the UCBG- UNIRAD trialSylvie Giacchetti, Enora Laas, Thomas Bachelot, et al.
Breast (Edinburgh, Scotland)|May 8, 2020
Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohortSophie Frank, Matthieu Carton, Coraline Dubot, et al.
Cancers|February 25, 2023
Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational StudyHélène François-Martin, Audrey Lardy-Cléaud, Barbara Pistilli, et al.
Therapeutic Advances in Medical Oncology|February 22, 2021
Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME programMarion Bertho, Julien Fraisse, Anne Patsouris, et al.
Therapeutic Advances in Medical Oncology|January 27, 2022
Real-world evidence of the management and prognosis of young women (⩽40 years) with <i>de novo</i> metastatic breast cancerAmélie Mallet, Amélie Lusque, Christelle Levy, et al.
JNCI Cancer Spectrum|January 25, 2021
Prediction of Breast Cancer Treatment-Induced Fatigue by Machine Learning Using Genome-Wide Association DataSangkyu Lee, Joseph O Deasy, Jung Hun Oh, et al.
Clinical Pharmacology and Therapeutics|August 24, 2025
Association Between Daily Timing of Everolimus and Survival in High-Risk HR+/HER2- Early Breast Cancer: A Sub-Analysis of the UCBG-UNIRAD TrialEnora Laas, Anne-Sophie Hamy, Thomas Bachelot, et al.
British Journal of Cancer|November 14, 2019
Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohortAmélie Darlix, Guillaume Louvel, Julien Fraisse, et al.
The Lancet. Oncology|August 13, 2013
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trialDavid Cameron, Julia Brown, Rebecca Dent, et al.
Pageof 14

Showing results (121-130 of 140) with videos related to

Sort By:
Pageof 14
European Journal of Cancer (Oxford, England : 1990)|September 30, 2018
UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancerMario Campone, Magali Lacroix-Triki, Lise Roca, et al.
Ebiomedicine|May 8, 2024
Association between endocrine adjuvant therapy intake timing and disease-free survival in patients with high-risk early breast cancer: results of a sub-study of the UCBG- UNIRAD trialSylvie Giacchetti, Enora Laas, Thomas Bachelot, et al.
Breast (Edinburgh, Scotland)|May 8, 2020
Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohortSophie Frank, Matthieu Carton, Coraline Dubot, et al.
Cancers|February 25, 2023
Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational StudyHélène François-Martin, Audrey Lardy-Cléaud, Barbara Pistilli, et al.
Therapeutic Advances in Medical Oncology|February 22, 2021
Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME programMarion Bertho, Julien Fraisse, Anne Patsouris, et al.
Therapeutic Advances in Medical Oncology|January 27, 2022
Real-world evidence of the management and prognosis of young women (⩽40 years) with <i>de novo</i> metastatic breast cancerAmélie Mallet, Amélie Lusque, Christelle Levy, et al.
JNCI Cancer Spectrum|January 25, 2021
Prediction of Breast Cancer Treatment-Induced Fatigue by Machine Learning Using Genome-Wide Association DataSangkyu Lee, Joseph O Deasy, Jung Hun Oh, et al.
Clinical Pharmacology and Therapeutics|August 24, 2025
Association Between Daily Timing of Everolimus and Survival in High-Risk HR+/HER2- Early Breast Cancer: A Sub-Analysis of the UCBG-UNIRAD TrialEnora Laas, Anne-Sophie Hamy, Thomas Bachelot, et al.
British Journal of Cancer|November 14, 2019
Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohortAmélie Darlix, Guillaume Louvel, Julien Fraisse, et al.
The Lancet. Oncology|August 13, 2013
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trialDavid Cameron, Julia Brown, Rebecca Dent, et al.
Pageof 14